New Test Nasal Spray Reduces Infection with Virus Causing COVID by 62%

The trial was conducted in India between April and July 2021. It involved 556 participants, 275 used pHOXWELL and 281 used a placebo, 3 times a day. After forty-five days, the researchers measured the amount of COVID-19 antibodies each user on any of the equipment possessed.

The team found that the nasal spray was and that after forty-five days, 13. 1% of other people in the organization who used it had antibodies to the COVID-19 virus, compared to 34. 5% of the organization that won the placebo. shows that the use of pHOXWELL especially reduces the risk of COVID-19.

The researchers also found that other people who used the nasal spray were less likely to experience symptoms than those who received the placebo. No serious side effects were reported in any of the organizations and participants noted that the nasal spray was easy to use.

Professor Rakesh Uppal, Professor of Cardiovascular Surgery at Queen Mary University of London, Director of Barts Life Sciences, said: “pHOXWELL presents a significant advance in preventing the progression of COVID-19. Now we have an effective tool, which in the past was lacking, to combat this virus, and it is designed to offer greater coverage against COVID-19, in addition to vaccines, masks and hand washing. “

“I am immensely proud of everyone who participated in this event and am incredibly grateful to the participants who dedicated their time to getArray. “

The purpose of the researchers is to start generating and distributing the remedy in India as a first step. Subsequently, they will seek to expand to other countries.

The treatment will be, specifically, in areas of the world where the acceptance of the vaccine remains low and there is a shortage of private protective devices for those who need it. significant tension in the global economy.

Please indicate the appropriate maximum category to facilitate the processing of your application

Thank you for taking the time to provide your feedback to the editors.

Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.

Leave a Comment

Your email address will not be published. Required fields are marked *